ARCHIVES

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

DCBDC Advisors Table Gl SPORE Over Pancreatic Cancer Research Requirement

March 17, 1995

Consructio Needs Over Next Five Years Total Estimated $696 Million; NCI Share-$132 Million

January 19, 1979

FDA News:: ODAC Commends Ciba For Design Of Trials Legal Issues:

January 10, 1997

Largest Oncological Society Exerts Clout, Getting Results

June 24, 1983

Senate Approves Supplemental Funds For NIH and FDA.

May 23, 2008

ACCC Established FCCC Special Interest Group

April 11, 1986